Inoperable Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)Phase 1/2NCT04086485Papers
Lu-177-DOTATATE
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
What the film says
This trial is for advanced neuroendocrine cancers that have progressed on at least one line of therapy, in adults: poorly differentiated neuroendocrine carcinoma, or grade 3 well differentiated neuroendocrine tumors.
The idea: add an oncolytic virus, SVV 001, to the immunotherapies nivolumab and ipilimumab. Groups receive a single dose or multiple doses of the virus, to find the highest dose and frequency that patients tolerate. Seneca Therapeutics is listed as a collaborator.
This phase 1 trial plans 36 patients. At the University of Miami, Peter Hosein leads it.
Public record; not medical advice.
Sources behind this film
Advanced neuroendocrine cancers progressed on at least one line of therapy; poorly differentiated carcinoma or grade 3 well differentiated tumors; adults; Oncolytic virus SVV-001 added to nivolumab and ipilimumab; Single dose or multiple doses, to find the highest tolerated dose and frequency; Seneca Therapeutics is listed as a collaborator (+2 more lines)
The drug
SVV-001 will be administered intratumorally as a single dose on Day 1; or as multiple doses on Days 1, 15, 29, 43, 57, and 71. The virus dose levels per SVV-001 treatment are as follows: * 2.2 × 10^8 Viral Genomes (VG) (starting dose) * 2.2 × 10^9 VG * 2.2 × 10^10 VG
Nivolumab will be administered via intravenous (IV) injection at a dose of 240 mg, once every two weeks starting on Day 15 until Day 85 during SVV-001 therapy. Nivolumab will be administered once every four weeks during the maintenance period for up to 2 years.
The study
The purpose of this study is to determine: 1. The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 2. The highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 3.
The highest dose and frequency of dosing of the trial intervention that targets neuroendocrine tumors with at least the same degree of effectiveness and tolerability as currently available (standard of care) treatments for patients with neuroendocrine tumors.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.